VIS-101 is a dual inhibitor of vascular endothelial growth factor A (VEGF‑A) and angiopoietin‑2 (ANG‑2), engineered to enhance binding capacity and affinity for both targets. The agent is being developed by Visara, a subsidiary of NovaBridge, with the goal of improving treatment durability while maintaining strong visual outcomes.

The phase 2a study enrolled 38 treatment‑naïve patients with wet AMD in China. Participants were randomly assigned to receive either a 6‑mg dose (n=25) or a 3‑mg dose (n=13) of intravitreal VIS-101. The primary objectives were safety and pharmacokinetics, while secondary measures included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) on optical coherence tomography, and the need for additional treatment.

Across both dosing groups, VIS-101 produced consistent and clinically meaningful responses. Patients experienced average BCVA gains exceeding 10 ETDRS letters, alongside median CST reductions of roughly 100 to 150 microns. Durability signals were notable: nearly two-thirds of participants did not require retreatment at four months, and approximately half remained treatment-free at six months following the loading phase.

Safety findings were also reassuring. Investigators reported no dose-limiting toxicities. No treatment-emergent adverse events occurred in the lower-dose cohort, and only two such events were observed among patients receiving the higher dose.

Company leadership expressed optimism that these results support VIS-101’s differentiated design and long-term potential. Based on the phase 2a data, NovaBridge plans to launch a dose-ranging phase 2b study in the second half of this year, with a global phase 3 development program anticipated to begin in 2027.